Page 55 - CIBERES-2015-eng

Most relevant scientific articles
Research Groups
MoLina r, MarraDes rM, augé JM, esCuDero JM, viñoLas n, reguart n et aL. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.American jour- nal of respiratory and critical care medicine. 2015;.
Faner r., gutierrez-saCristan a., Castro-aCosta a., grosDiDier s., gan W., sánChez-Mayor M. et aL. Mo- lecular and clinical diseasome of comorbidities in exac- erbated COPD patients. European Respiratory Journal. 2015;46(4):1001-1010.
hoLgate s., agusti a., strieter r.M., anDerson g.P., FogeL r., BeL e. et aL. Drug development for airway dis- eases: Looking forward. Nature Reviews Drug Discovery. 2015;14(6):367-368.
WooDruFF P.g., agusti a., roChe n., singh D., Martín- ez F.J.. Current concepts in targeting chronic obstruc- tive pulmonary disease pharmacotherapy: Making pro- gress towards personalised management. The Lancet. 2015;385(9979):1789-1798.
Lange P., CeLLi B., agusti a., Jensen g.B., Divo M., Fan- er r. et aL. Lung-function trajectories leading to chronic obstructive pulmonary disease. New England Journal of Medicine. 2015;373(2):111-122.
Highlights
During 2015, the group 10 has produced the follow- ing main results:
• ThelineofthenaturalhistoryofCOPDhasshown that COPD can develop not only as a result of deterioration in lung function associated with smoking, but also as a consequence of poor lung development. The results of this study have been published in the NEJM.
• Network medicine applied to the study of COPD comorbidities, has shown the common molecular pathways between several COPD comorbidities in exacerbated COPD patients, results have been published in ERJ.
• Workontheidentificationofbiomarkersassociat- ed to lung cancer has been published in AJRCCM.
In terms of projects the group has initiated a new one funded by the ISCIII (PI15 / 00799) with co-IPs Alvar Agusti / Rosa Faner. The group continued the participation in the projects of the COPD PCI and continued with active projects funded in previous years by SEPAR and FUCAP.
As for clinical guidelines, the group leader Dr. Alvar Agustí is a member of the scientific committee of GOLD (Global Initiative for Chronic Obstructive Lung Disease).
Institution: Fundación de Investigación Sanitaria de las Islas Baleares Ramon Llull (FISIB) Contact: Ctra. Sóller Km. 12. Recinto Hospital Joan March. 07110 Bunyola · Tel.: 93 227 17 01 E.mail: [email protected] · Website: http://www.isciii.es
CIBERES I Annual report 2015 I 55